SNCA and Parkinson disease: This is the first study targeting alpha-synuclein in the intestine and spinal cord (central nervous system), supporting the potential use of anti-alpha-synuclein shRNA-MC RVG-EV as a therapy to delay or halt Parkinson’s disease pathology progression.